Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia

Ashley N. Mays, Neil Osheroff, Yuanyuan Xiao, Joseph L. Wiemels, Carolyn A. Felix, Jo Ann W Byl, Kandeepan Saravanamuttu, Andrew Peniket, Robert Corser, Cherry Chang, Christine Hoyle, Anne N. Parker, Syed K. Hasan, Francesco Lo-Coco, Ellen Solomon, David Grimwade

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin. We previously have shown that mitoxantrone preferentially induces topoII-mediated DNA damage in a "hotspot region" within PML intron 6. To investigate mechanisms underlying epirubicin-associated t-APL, t(15; 17) genomic breakpoints were characterized in 6 cases with prior breast cancer. Significant breakpoint clustering was observed in PML and RARA loci (P = .009 and P = .017, respectively), with PML breakpoints lying outside the mitoxantrone-associated hotspot region. Recurrent breakpoints identified in the PML and RARA loci in epirubicin-related t-APL were shown to be preferential sites of topoII-induced DNA damage, enhanced by epirubicin. Although site preferences for DNA damage differed between mitoxantrone and epirubicin, the observation that particular regions of the PML and RARA loci are susceptible to these agents may underlie their respective propensities to induce t-APL.

Original languageEnglish
Pages (from-to)326-330
Number of pages5
JournalBlood
Volume115
Issue number2
DOIs
Publication statusPublished - Jan 14 2010

Fingerprint

Epirubicin
Genetic Translocation
Acute Promyelocytic Leukemia
Mitoxantrone
Type II DNA Topoisomerase
DNA Damage
DNA
Therapeutics
Introns
Cluster Analysis
Genes
Breast Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. / Mays, Ashley N.; Osheroff, Neil; Xiao, Yuanyuan; Wiemels, Joseph L.; Felix, Carolyn A.; Byl, Jo Ann W; Saravanamuttu, Kandeepan; Peniket, Andrew; Corser, Robert; Chang, Cherry; Hoyle, Christine; Parker, Anne N.; Hasan, Syed K.; Lo-Coco, Francesco; Solomon, Ellen; Grimwade, David.

In: Blood, Vol. 115, No. 2, 14.01.2010, p. 326-330.

Research output: Contribution to journalArticle

Mays, AN, Osheroff, N, Xiao, Y, Wiemels, JL, Felix, CA, Byl, JAW, Saravanamuttu, K, Peniket, A, Corser, R, Chang, C, Hoyle, C, Parker, AN, Hasan, SK, Lo-Coco, F, Solomon, E & Grimwade, D 2010, 'Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia', Blood, vol. 115, no. 2, pp. 326-330. https://doi.org/10.1182/blood-2009-07-235051
Mays, Ashley N. ; Osheroff, Neil ; Xiao, Yuanyuan ; Wiemels, Joseph L. ; Felix, Carolyn A. ; Byl, Jo Ann W ; Saravanamuttu, Kandeepan ; Peniket, Andrew ; Corser, Robert ; Chang, Cherry ; Hoyle, Christine ; Parker, Anne N. ; Hasan, Syed K. ; Lo-Coco, Francesco ; Solomon, Ellen ; Grimwade, David. / Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. In: Blood. 2010 ; Vol. 115, No. 2. pp. 326-330.
@article{90bbc866de8f4a7692dcbc070ad0c3a7,
title = "Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia",
abstract = "Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin. We previously have shown that mitoxantrone preferentially induces topoII-mediated DNA damage in a {"}hotspot region{"} within PML intron 6. To investigate mechanisms underlying epirubicin-associated t-APL, t(15; 17) genomic breakpoints were characterized in 6 cases with prior breast cancer. Significant breakpoint clustering was observed in PML and RARA loci (P = .009 and P = .017, respectively), with PML breakpoints lying outside the mitoxantrone-associated hotspot region. Recurrent breakpoints identified in the PML and RARA loci in epirubicin-related t-APL were shown to be preferential sites of topoII-induced DNA damage, enhanced by epirubicin. Although site preferences for DNA damage differed between mitoxantrone and epirubicin, the observation that particular regions of the PML and RARA loci are susceptible to these agents may underlie their respective propensities to induce t-APL.",
author = "Mays, {Ashley N.} and Neil Osheroff and Yuanyuan Xiao and Wiemels, {Joseph L.} and Felix, {Carolyn A.} and Byl, {Jo Ann W} and Kandeepan Saravanamuttu and Andrew Peniket and Robert Corser and Cherry Chang and Christine Hoyle and Parker, {Anne N.} and Hasan, {Syed K.} and Francesco Lo-Coco and Ellen Solomon and David Grimwade",
year = "2010",
month = "1",
day = "14",
doi = "10.1182/blood-2009-07-235051",
language = "English",
volume = "115",
pages = "326--330",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia

AU - Mays, Ashley N.

AU - Osheroff, Neil

AU - Xiao, Yuanyuan

AU - Wiemels, Joseph L.

AU - Felix, Carolyn A.

AU - Byl, Jo Ann W

AU - Saravanamuttu, Kandeepan

AU - Peniket, Andrew

AU - Corser, Robert

AU - Chang, Cherry

AU - Hoyle, Christine

AU - Parker, Anne N.

AU - Hasan, Syed K.

AU - Lo-Coco, Francesco

AU - Solomon, Ellen

AU - Grimwade, David

PY - 2010/1/14

Y1 - 2010/1/14

N2 - Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin. We previously have shown that mitoxantrone preferentially induces topoII-mediated DNA damage in a "hotspot region" within PML intron 6. To investigate mechanisms underlying epirubicin-associated t-APL, t(15; 17) genomic breakpoints were characterized in 6 cases with prior breast cancer. Significant breakpoint clustering was observed in PML and RARA loci (P = .009 and P = .017, respectively), with PML breakpoints lying outside the mitoxantrone-associated hotspot region. Recurrent breakpoints identified in the PML and RARA loci in epirubicin-related t-APL were shown to be preferential sites of topoII-induced DNA damage, enhanced by epirubicin. Although site preferences for DNA damage differed between mitoxantrone and epirubicin, the observation that particular regions of the PML and RARA loci are susceptible to these agents may underlie their respective propensities to induce t-APL.

AB - Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin. We previously have shown that mitoxantrone preferentially induces topoII-mediated DNA damage in a "hotspot region" within PML intron 6. To investigate mechanisms underlying epirubicin-associated t-APL, t(15; 17) genomic breakpoints were characterized in 6 cases with prior breast cancer. Significant breakpoint clustering was observed in PML and RARA loci (P = .009 and P = .017, respectively), with PML breakpoints lying outside the mitoxantrone-associated hotspot region. Recurrent breakpoints identified in the PML and RARA loci in epirubicin-related t-APL were shown to be preferential sites of topoII-induced DNA damage, enhanced by epirubicin. Although site preferences for DNA damage differed between mitoxantrone and epirubicin, the observation that particular regions of the PML and RARA loci are susceptible to these agents may underlie their respective propensities to induce t-APL.

UR - http://www.scopus.com/inward/record.url?scp=75649084232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75649084232&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-07-235051

DO - 10.1182/blood-2009-07-235051

M3 - Article

VL - 115

SP - 326

EP - 330

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -